You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
李氏大药厂(00950.HK)中期收入同比增长7.01%至6.08亿港元
格隆汇 08-29 17:33

格隆汇8月29日丨李氏大药厂(00950.HK)公布,截至2019年6月30日止6个月,集团实现营业收入6.08亿港元,同比增长7.01%;公司拥有人应占溢利3829.4万港元;每股基本盈利6.47港仙;拟派发中期股息每股0.018港元。

公告表示,尽管于回顾季度持续面对市场挑战及人民币疲弱,集团仍录得令人鼓舞的销售增长,并于年度第二季度重回双位数字增长,并于2019年上半年恢复整体收益增长。于回顾期内,中国经营环境的通胀压力及原料药(API)成压力持续。

然而,该等不利影响因成控制及生产力提升措施而大幅减轻,令集团得以维持稳定的毛利率水平。随着新产品推出市场,集团于回顾季度投放更多资源在新推出的产品上,同时在2019年上半年仍能维持适当的销售开支与收益比率。在南沙基地的业务规模扩大,行政成不断上涨的情况下,集团的整体营运及财务表现处于健康稳定的状况,令集团得以大量投资以加快开发新药。

此外,集团已就眼科研发业务(即现已成为集团拥有50.1%权益附属公司China Ophthalmology Focus Limited向国际知名投资者寻求额外资金,从而于回顾季度内加强集团资产负债表及确保充足流动资金以开发COPFL的新产品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account